Tweets by @cellcentric

CCS1477, our first-in-class p300/CBP inhibitor arose from a deep foundation in epigenetics. See: cellcentric.com/company/histor… pic.twitter.com/4JjgcFTZPk

CellCentric continues to build its clinical development team. CCS1477 for prostate and haem cancers. pic.twitter.com/cwcblz6TDG

Targeted drug discovery & development: CCS1477 for treating specific tumour types via specific cancer drivers. pic.twitter.com/x1eV70BhpZ

Neil, CellCentric’s Research Director, at parliament today helping represent UK biotech innovation. @BIA_UK pic.twitter.com/HudhvFg3yJ

First-in-class p300/CBP inhibitor CCS1477: targeted drug discovery/development to meet specific patient needs pic.twitter.com/Uyaxh57L3U

CellCentric’s CEO, Will, at the Future of Healthcare Investor Forum this morning. @BIA_UK @LSEGplc pic.twitter.com/AneYthuaRx